Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-23
2011-08-23
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S006120, C435S375000
Reexamination Certificate
active
08003620
ABSTRACT:
Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
REFERENCES:
patent: 5708160 (1998-01-01), Goh et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6100077 (2000-08-01), Sturley et al.
patent: 6344548 (2002-02-01), Farese, Jr. et al.
patent: 6444427 (2002-09-01), Ludwig et al.
patent: 6512099 (2003-01-01), Omura et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6607893 (2003-08-01), Ramharack et al.
patent: 6822141 (2004-11-01), Lardizabal et al.
patent: 6867039 (2005-03-01), Monia et al.
patent: 7414033 (2008-08-01), Monia et al.
patent: 7745691 (2010-06-01), Farese et al.
patent: 7795283 (2010-09-01), Birch et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0119138 (2002-08-01), Cases et al.
patent: 2002/0127627 (2002-09-01), Ramharack et al.
patent: 2002/0193315 (2002-12-01), Omura et al.
patent: 2003/0028923 (2003-02-01), Lardizabal et al.
patent: 2003/0073103 (2003-04-01), Ludwig et al.
patent: 2003/0100480 (2003-05-01), Smith et al.
patent: 2003/0104414 (2003-06-01), Attersand
patent: 2003/0115632 (2003-06-01), Lardizabal et al.
patent: 2003/0124126 (2003-07-01), Cases et al.
patent: 2003/0152574 (2003-08-01), Logan et al.
patent: 2003/0161831 (2003-08-01), Cases et al.
patent: 2003/0170691 (2003-09-01), Gimeno et al.
patent: 2003/0200563 (2003-10-01), Butler et al.
patent: 2003/0202968 (2003-10-01), Cases et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0054177 (2004-03-01), Otake et al.
patent: 2004/0058820 (2004-03-01), Hagmann et al.
patent: 2004/0076977 (2004-04-01), Georges et al.
patent: 2004/0078836 (2004-04-01), Farese et al.
patent: 2004/0107459 (2004-06-01), Lardizabal et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0185559 (2004-09-01), Monia et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 1308459 (2003-05-01), None
patent: WO 99/67268 (1999-12-01), None
patent: WO 00/78961 (2000-12-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/77389 (2001-10-01), None
patent: WO 02/08260 (2002-01-01), None
patent: WO 02/062954 (2002-08-01), None
patent: WO 02/086085 (2002-10-01), None
patent: WO 03/004630 (2003-01-01), None
Chen and Farese, Jr., “Inhibition of triglyceride synthesis as a treatment strategy for obesity,” Arterioscler. Thromb. Vasc. Biol. 25:482-486 (2005).
International Search Report and Written Opinion dated Aug. 18, 2008 (PCT/US07/75297).
Buhman et al., “DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis” J. Biol. Chem. (2002) 277:25474-25479.
Cases et al., “Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis” PNAS (1998) 95:13018-13023.
Cases et al., “Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family member” J. Biol. Chem. (2001) 276:38870-38876.
Chen et al., “Increased insulin and leptin sensitivity in mice lacking acyl CoA: diacylglycerol acyltransferase 1” J. Clin. Invest (2002) 109:1049-1055.
Chen et al., “Leptin modulates the effects of acyl CoA: diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands” J. Clin. Invest. (2002) 109:175-181.
Cheng et al., “Human acyl-CoA: diacylglycerol acyltransferase is a tetrameric protein” Biochem. J. (2001) 359:707-714.
Chin, “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Caroline on Mar. 14, 2002.
European Partial Search Report for Application # EP 04722144.5 dated Feb. 6, 2007.
European Partial Search Report for Application # EP 04722144.5 dated Jun. 22, 2007.
Farese et al., “Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase” Curr. Opin. Lipidol. (2000) 11:229-234.
Lardizabal et al., “DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides fromMortierella ramannianawith diacylglycerol acyltransferase activity” J. Biol. Chem. (2001) 276: 38862-38869.
Ludwig et al., “DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women” Clin. Genet. (2002) 62:68-73.
Meegalla et al., “Concerted elevation of acyl-coenzyme A: diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin” Biochem. Biophys. Res. Commun. (2002) 298:317-323.
Murray et al., “Inhibition of DGAT1 with a Novel Optimized Antisense Inhibitor Lowers Plasma Glucose Levels” Diabetes (2003) 52, A300:XP009077409.
Oelkers et al., “Characterization of two human genes encoded acyl coenzyme A: cholesterol acyltransferase-related enzymes” J. Biol. Chem. (1998) 273:26765-26771.
Smith et al., “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT” Nat. Genet. (2000) 25:87-90.
Tabata et al., “Xanthohumols, diacylglycerol acyltransferase inhibitors, fromHumulus lupulus” Phytochemistry (1997) 46: 683-687.
Tomoda et al., “Roselipins, inhibitors of diacylglycerol acyltransferase, produced byGliocladium roseumKF-1040” J. Antibiot. (1999) 52:689-694.
Waterman et al., “Distinct ontogenic patterns or overt and latent DGAT activities of rat liver microsomes” J. Lipid. Res. (2002) 43:1555-1562.
Yu et al., “Expression of either an antisense RNA or a dominant negative mutant of diacylglycerol acyltransferase (DGAT) blocks fat accumulation in insulin/dexamethasone induced 3T3-L1 cells” 100, 18 Supp. (1999): I.745.
Yu et al., “Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes” J. Biol. Chem. (2002) 277:50876-50884.
Supplemental Partial European Search Report for Application # EP 07813825 dated Sep. 29, 2009 (P052328EP).
Yamaguchi, et al., “DGAT1 ASO treatment reduces hepatic fibrosis without improving hepatic steatosis in DB/DB mice fed methionine choline deficient diets,” XP009123004, ISSN:0270-9139,Hepatology, 44(5):663A (2006). Abstract.
Branch et al., “A good antisense molecule is hard to find” TIBS (1998) 23:45-50.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
New England Biolabs 1998/1999 Catalog, cover page, pages 121 and 284.
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Yamaguchi et al., “DGAT1 ASO tratment reduces hepatic fibrosis without improving hepatic steatosis in DB/DB mice fed methionine choline deficient diets” Hepatology (2006) 44(4) Suppl. 1, p. 663A.
European Search Report for Application EP 07813825 dated Sep. 21, 2009.
International Search Report for Int. Application No. PCT/US04/06083 dated Jan. 24, 2006.
Office Action for U.S. Appl. No. 10/803,482 dated Nov. 1, 2006.
Final Rejection for U.S. Appl. No. 10/803,482 dated Oct. 18, 2007.
Office Action for U.S. Appl. No. 12/173,744 dated Feb. 18, 2009.
Bhanot Sanjay
Monia Brett P.
Yu Xing-Xian
ISIS Pharmaceuticals Inc.
Jones Day
McGarry Sean
LandOfFree
Compositions and their uses directed to diacylglycerol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and their uses directed to diacylglycerol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and their uses directed to diacylglycerol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2750200